Report from the 62nd American Society of Hematology Annual Meeting — Benign Hematology

Highlights of the latest research

Presenters at the recent meeting of the American Society of Hematology (ASH; December 5–8, 2020, all virtual) reported the latest research in hematology. Here, NEJM Journal Watch Oncology and Hematology Associate Editor Brady L. Stein, MD, MHS, describes the key findings. The original abstracts can be found on the ASH website.

Prophylactic TXA Does Not Protect Against Bleeding in Hematologic Malignancy

Christine Judge

Prophylactic tranexamic acid (TXA) is not effective in reducing WHO Grade 2 or higher bleeding in severely thrombocytopenic patients undergoing treatment for hematologic malignancy, researchers report (abstract 2).

Among 327 patients randomized to receive either TXA or placebo as an adjunct to routine platelet transfusion therap…

Authors

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Christine Judge, MS

Cara Adler, MS

Report from the 62nd American Society of Hematology Annual Meeting — Benign Hematology

Topics

Prophylactic TXA Does Not Protect Against Bleeding in Hematologic Malignancy

Authors